Siolta Therapeutics is a clinical-stage biotech developing defined-consortia live biotherapeutic products using its Precision Symbiotics Platform. Its lead product, STMC-103H, is a defined-consortia Live Biotherapeutic Product (LBP) in phase 2 development aimed at preventing atopic diseases in newborns, including atopic dermatitis, food allergy, and asthma. The company is also advancing preclinical programs STMC-105 (recurrent bacterial vaginosis) and STMC-106 (necrotizing enterocolitis) for indications with no FDA-approved products. Siolta received an NIH grant to further preclinical work on STMC-106 and is collaborating with Johns Hopkins University to help select a clinical candidate for future trials. The $12 million Series C financing will support further clinical development of STMC-103H and broader exploration of microbiome-based treatments in maternal and infant health. The company states it is pursuing therapeutics that target underlying drivers of disease and has advanced multiple programs into clinical and preclinical development. Siolta Therapeutics operates a live biotherapeutic product (LBP) platform to develop microbiome-based medicines and companion diagnostics targeting prevention and treatment of chronic inflammatory diseases. Its lead program, STMC-103H, focuses on allergic diseases with the aim of stopping asthma before it starts by disrupting the atopic march. The company completed a Phase 1b first-in-human safety trial in adults, adolescents, and children, has scaled manufacturing to support phase 2 studies, and received Fast Track designation from the FDA for its lead prevention program. Siolta plans to use new capital to advance clinical proof-of-concept trials testing the efficacy of its lead LBP product. The company has expanded its executive team with additions including John Martin, PhD as an executive advisor and Rich Shames, MD as chief medical officer. Founded in 2016 and based in the San Francisco Bay Area, Siolta leverages expertise in microbiology, immunology, and bioinformatics to develop targeted microbial therapeutics.

Total raised

$42M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2024